Theravance SVP sells 31K shares in open trade

Theravance Biopharma, Inc. senior executive Rhonda Farnum, SVP, Commercial & Medical Affairs, sold a total of 31,067 ordinary shares of TBPH in open-market transactions on March 16, 2026, at prices ranging from $13.755 to $14.01.

Accepted by SEC EDGAR 03/18/2026 - 06:12 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Theravance Biopharma, Inc. senior executive Rhonda Farnum, SVP, Commercial & Medical Affairs, sold a total of 31,067 ordinary shares of TBPH in open-market transactions on March 16, 2026, at prices ranging from $13.755 to $14.01. After these sales, she directly owns 232,699 ordinary shares of the company.

Insider Trade Summary 10b5-1

Net Seller: 31,067 shares

Net Sell 3 txns

Insider Farnum Rhonda

Role SVP, COMM & MEDICAL AFFAIRS

Sold 31,067 shs ($434K)

Share of Position Sold 11.8%

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	7,767	$13.9163	$108K
Sale	Ordinary Shares	15,534	$14.00	$217K
Sale	Ordinary Shares	7,766	$13.9162	$108K

Holdings After Transaction: Ordinary Shares — 232,699 shares (Direct)

Holdings Before and After: Ordinary Shares, 263,766 to 232,699 shares (Direct)

Footnotes (1)

1. F1. This transaction was executed in multiple trades at prices from $13.755 to $14.01. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Rhonda Farnum report at Theravance Biopharma (TBPH)?

Rhonda Farnum reported selling 31,067 ordinary shares of Theravance Biopharma on March 16, 2026. The Form 4 shows three open-market sale transactions in ordinary shares, all executed on the same date, reducing but not eliminating her direct equity stake in the company.

What is Rhonda Farnum’s role at Theravance Biopharma (TBPH)?

Rhonda Farnum serves as Senior Vice President, Commercial & Medical Affairs at Theravance Biopharma. This senior leadership role means her equity transactions are reported on Form 4, giving investors visibility into how a key executive manages her personal ownership in the company’s ordinary shares.

How many Theravance Biopharma (TBPH) shares does Rhonda Farnum own after the sale?

After the reported transactions, Rhonda Farnum directly owns 232,699 ordinary shares of Theravance Biopharma. The Form 4’s final line item shows this post-transaction balance, indicating she retains a substantial personal stake in the company following the 31,067-share open-market sale.

At what prices were Theravance Biopharma (TBPH) shares sold in Rhonda Farnum’s Form 4?

The reported sale prices include weighted averages of $13.9163, $14.00, and $13.9162 per share. A footnote explains the trades were executed in multiple lots between $13.755 and $14.01, with the listed figures representing weighted average sale prices across those individual executions.

Was Rhonda Farnum’s Theravance Biopharma (TBPH) transaction an open-market sale?

Yes. Each transaction on the Form 4 is coded “S” and described as an open-market or private sale of non-derivative ordinary shares. The filing characterizes these as straightforward dispositions of common equity, rather than option exercises, gifts, tax withholdings, or derivative-related transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farnum Rhonda

(Last) (First) (Middle)

C/O THERAVANCE BIOPHARMA US, LLC

901 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, COMM & MEDICAL AFFAIRS

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	03/16/2026		S		7,767	D	$13.9163(1)	255,999	D
Ordinary Shares	03/16/2026		S		15,534	D	$14	240,465	D
Ordinary Shares	03/16/2026		S		7,766	D	$13.9162(1)	232,699	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices from $13.755 to $14.01. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

These transactions were executed in accordance with the reporting person's 10b5-1 plan dated 09/03/2025.

	/s/ Brett A. Grimaud, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)